Bio-Bridge Science Selected to Participate in Prestigious Study Targeting Health Care Solutions in Emerging Countries
24 May 2006 - 11:33PM
Business Wire
Bio-Bridge Science, Inc. (OTCBB:BGES) announced today its
participation in a study, entitled Private Sector Development in
Developing Countries: Targeting Local Health Needs through Health
Technology, which explores how small to medium enterprises can
address local health needs in Innovating Developing Countries
(IDCs) such as China, India, Brazil and South Africa. Two members
of the research team, Dr. Sarah E. Frew and Dr. Peter A. Singer,
visited Bio-Bridge Science's soon to be finished GMP lab facility
and met with senior management on May 15, 2006 in Beijing. As part
of the study, Bio-Bridge Science, Inc. will participate in
exploring ways that the domestic private sector can contribute to
the development of health technologies targeted to address local
health needs. The mission of Bio-Bridge Science, Inc. is to develop
and produce new vaccines and drugs to treat human diseases and
improve human health. "We are honored to be selected to participate
in this study," said Dr. Liang Qiao, Chief Executive Officer of
Bio-Bridge. "The exposure among many of the key thought and opinion
leaders in these countries will raise our profile in these key
markets. As a Company that has focused on developing cost-effective
vaccines for large unmet medical needs in countries such as China,
we believe that we are uniquely qualified to offer solutions to
these challenges." About Bio-Bridge Science: Bio-Bridge Science is
a biotechnology firm focused on the development of vaccines with
broad therapeutic and preventive applications. Through its wholly
owned subsidiary in Beijing, Bio-Bridge is developing a promising
new HIV Vaccine that is expected to enter clinical trials this year
in China. The vaccine, based on exclusive technology co-developed
by CEO Liang Qiao, an associate professor at Loyola University
Chicago's Strich School of Medicine, targets infection in mucosal
tissues, the first type of tissue attacked by HIV. The Chinese
government, mindful of the rapid expansion of AIDS in China has,
through the "Green Mile Policy", acted to expedite the approval of
domestically produced HIV Vaccines and has dramatically increased
its spending on AIDS-related research. In accordance with this
policy, Bio-Bridge expects to bring its therapeutic HIV Vaccine to
market as early as late 2008, far in advance of many other HIV
Vaccines currently in development. Bio-Bridge is currently
constructing a new $3 million state-of-the-art GMP research and
manufacturing facility in Beijing, which is expected to be
completed by mid-year. The facility will also be used to develop
vaccines against cervical cancer and colon cancer under the same
technology platform as the HIV vaccine.
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Bio Bridge Science Inc (CE) (OTCMarkets): 0 recent articles
More Bio-Bridge Science, Inc. News Articles